| CYXO Stock | | | SEK 0.03 0 10.34% |
Chairman
Dr. Bert Junno was Chairman of the Board at Cyxone AB since 2015. He is Doctor of Technology and Civil Engineer in Engineering Physics from Lunds Tekniska Hogskola. He founded and was CEO of WntResearch AB and developed Galecto Biotech AB from Forskarpatent i Syd ABs project portfolio. He is currently Director and CEO of Gabather AB and Director of Aptahem AB, Accequa AB and on the Advisory Board of Patent och registreringsverket. He previously was Director of Taurus Energy AB, Wntresearch AB, Jakten 7 AB, Balx 4 AB and Galecto Biotech AB, as well as CEO of Forskarpatent i Syd AB and Innovationspatent Sverige AB. He has also been active at Accequa AB. since 2015.
| Age | 53 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Phone | 46 7 08 88 21 72 |
| Web | https://www.cyxone.com |
Cyxone AB Management Efficiency
The company has return on total asset
(ROA) of
(0.5861) % which means that it has lost $0.5861 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(1.0658) %, meaning that it generated substantial loss on money invested by shareholders. Cyxone AB's management efficiency ratios could be used to measure how well Cyxone AB manages its routine affairs as well as how well it operates its assets and liabilities.
Cyxone AB , a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis and multiple sclerosis and treatments for virally induced acute respiratory disorders. The company was founded in 2015 and is headquartered in Malm, Sweden. Cyxone AB is traded on Stockholm Stock Exchange in Sweden. Cyxone AB (CYXO) is traded on Stockholm Exchange in Sweden and employs 8 people.
Management Performance
Cyxone AB Leadership Team
Elected by the shareholders, the Cyxone AB's board of directors comprises two types of representatives: Cyxone AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyxone. The board's role is to monitor Cyxone AB's management team and ensure that shareholders' interests are well served. Cyxone AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyxone AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Malin Berthold, Project Manager | |
| Theresa Olsen, Director | |
| Bert Junno, Chairman of the Board | |
| Ola Skanung, Interim Chief Executive Officer, Chief Financial Officer | |
| Mikael Lindstam, Chief Operating Officer, Director | |
| Erika Samuelsson, Chief Officer | |
| Saad Gilani, Director | |
| CarlMagnus Hogerkorp, COO CEO | |
Cyxone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyxone AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Cyxone Stock Analysis
When running Cyxone AB's price analysis, check to
measure Cyxone AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyxone AB is operating at the current time. Most of Cyxone AB's value examination focuses on studying past and present price action to
predict the probability of Cyxone AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyxone AB's price. Additionally, you may evaluate how the addition of Cyxone AB to your portfolios can decrease your overall portfolio volatility.